Impact of PLCG2 expression on Microglial Biology and Disease Pathogenesis in Alzheimer’s Disease
Open accessAbstract
Background: Alzheimer’s disease (AD) and other neurodegenerative diseases are typified by a robust microglial‐mediated immune response. Genetic studies have demonstrated that variants in microglial genes are linked to risk for AD. Phospholipase C gamma 2 (PLCG2), whose variants confer altered risk for AD, is a critical signaling element for various immune receptors and is a key regulatory hub gene for immune signaling. To date, it is known that PLCG2 might be important in AD due to the pervious findings that a hypermorphic variant in PLCG2, rs72824905, is protective against AD risk. However, the role of PLCG2 has not yet been comprehensively explored. We believe that genetic mouse models are needed to further clarify the role of PLCG2 in plaque‐associated microglia and to determine whether decreased PLCG2 expression in plaque‐associated microglia favors disease exacerbation or attenuation. Method: To investigate the impact of reduced PLCG2 gene expression on microglia biology and disease pathology, we have generated PLCG2 inactivation mice, all crossed onto the 5XFAD amyloidogenic murine model of AD. Result: We provide data demonstrating that in individuals with AD, there is increased expression of PLCG2 in the brain, a finding that is recapitulated in 5XFAD mice. We show that reduced PLCG2 gene expression program microglial phenotypes in 5XFAD mice, affect plaque pathology, and drive distinct transcriptional phenotypes of microglia in the presence of amyloid pathology. Analysis of plaque pathology revealed that 5XFAD PLCG2 inactivation mice have elevated plaque burden. Compared to 5XFAD mice, behavioral analysis of 5XFAD with PLCG2 inactivation mice demonstrated an impaired performance in the Y maze assay, reflecting impaired cognitive decline. Our data suggest that the inactivation of PLCG2 had accelerated and exacerbated disease‐related pathology. Conclusion: Together, our findings provide evidence that PLCG2 plays an important role in AD pathophysiology, indicating PLCG2 as a potential new therapeutic target for AD.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The role of PLCG2 has not yet been comprehensively explored.
“However, the role of PLCG2 has not yet been comprehensively explored (Tsai et al., 2021; Maguire et al., 2021).”
From Plcg2M28L Interacts With High Fat/High Sugar Diet to Accelerate Alzheimer’s Disease-Relevant Phenotypes in Mice (2022) · cites this paper as Tsai et al., 2021
Reduced PLCG2 gene expression affects plaque pathology in 5XFAD mice.
“A previous study has reported that reduced PLCG2 gene expression alters microglial phenotypes in 5XFAD mice, affects plaque pathology, and drives distinct transcriptional phenotypes of microglia in the presence of amyloid pathology (Tsai et al., 2021).”
From Plcg2M28L Interacts With High Fat/High Sugar Diet to Accelerate Alzheimer’s Disease-Relevant Phenotypes in Mice (2022) · cites this paper as Tsai et al., 2021
Reduced PLCG2 gene expression drives distinct transcriptional phenotypes of microglia in the presence of amyloid pathology.
“A previous study has reported that reduced PLCG2 gene expression alters microglial phenotypes in 5XFAD mice, affects plaque pathology, and drives distinct transcriptional phenotypes of microglia in the presence of amyloid pathology (Tsai et al., 2021).”
From Plcg2M28L Interacts With High Fat/High Sugar Diet to Accelerate Alzheimer’s Disease-Relevant Phenotypes in Mice (2022) · cites this paper as Tsai et al., 2021
Reduced PLCG2 gene expression alters microglial phenotypes in 5XFAD mice.
“A previous study has reported that reduced PLCG2 gene expression alters microglial phenotypes in 5XFAD mice, affects plaque pathology, and drives distinct transcriptional phenotypes of microglia in the presence of amyloid pathology (Tsai et al., 2021).”
From Plcg2M28L Interacts With High Fat/High Sugar Diet to Accelerate Alzheimer’s Disease-Relevant Phenotypes in Mice (2022) · cites this paper as Tsai et al., 2021
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited by
Sorted by citations
Oblak, A. L., Kotredes, K. P., Pandey, R. S., Reagan, A. M., Ingraham, C., Perkins, B., Lloyd, C., Baker, D., Lin, P. B., Soni, D. M., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.886575 · Cited by 23 · see citing works
“However, the role of PLCG2 has not yet been comprehensively explored (Tsai et al., 2021; Maguire et al., 2021).”
BackgroundInfluentialSelf-citation
- Authors
- Tsai, A. P., Lin, P. B., Dong, C., Moutinho, M., Liu, Y., Bissel, S. J., Oblak, A. L., Nho, K., Lamb, B. T., & Landreth, G. E.
- Affiliations
- Indiana University School of Medicine (US)
- Indiana University Indianapolis (US)
- Corresponding author
- Tsai, Andy Po‐Yi
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2021-12
- Volume
- 17
- Issue
- S2
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W4206453736
- Cited by
- 1
- References
- 0
- Citations by year
- 2022: 1
- FWCI
- 0.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Alzheimer s & Dementia (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- PLCγ2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
